Galaxy Biomedical Investment Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 77.977 million compared to CNY 115.487 million a year ago. Operating income was CNY 3.435 million compared to operating loss of CNY 7.758 million a year ago. Net income was CNY 1.359 million compared to net loss of CNY 8.627 million a year ago. Basic earnings per share from continuing operations was CNY 0.011 compared to basic loss per share from continuing operations of CNY 0.072 a year ago.